Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

IRadimed Q3 revenue beats estimates, narrows guidance 

By Reuters News


Overview

  • MRI-compatible device maker's Q3 revenue grew 14% yr/yr, beating analyst expectations

  • Q3 non-GAAP diluted EPS rose 17% yr/yr to $0.55

  • Company narrowed full-year 2026 revenue and EPS guidance


Outlook

  • Company expects Q4 revenue of $25.0 mln to $26.5 mln

  • Company lowers full-year 2026 revenue outlook to $91.6 mln to $93.1 mln

  • Company cuts full-year 2026 GAAP diluted EPS forecast to $1.90 to $1.94


Result Drivers

  • NEW PRODUCT LAUNCH - Co said Q3 revenue growth was driven by continued successful launch of 3870 MR IV pump

  • RECORD BOOKINGS - Co said quarterly bookings set new records, helped by higher monitor units and 45% yr/yr increase in domestic pump channels

  • PRODUCT CONFIGURATION SHIFT - Over 70% of pump bookings were for 'quad stack' setup, as customers accelerated replacement of older models


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$24.20 mln

$23.47 mln (3 Analysts)

Q3 EPS

$0.51


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for IRADIMED CORPORATION is $118.00, about 37.6% above its October 29 closing price of $85.74

  • The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 43 three months ago


Reuters Recommended Reads

  • Oct 29 - Ultrasound device maker Butterfly Network Q3 revenue beats on Embedded partnerships

  • Oct 29 - Penumbra Q3 revenue beats estimates on thrombectomy growth

  • Oct 29 - Stryker Q3 sales, adjusted profit miss estimates despite higher unit volumes


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.